[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"glottic-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:glottic-carcinoma":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,82],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100623031","precision-medicine-mri-guided-stereotactic-ablative-radiotherapy-mri-sabr-for-early-stage-glottic-laryngeal-cancer-100623031",false,"NCT07391345","Precision Medicine: MRI-Guided Stereotactic Ablative Radiotherapy (MRI-SABR) for Early-Stage Glottic Laryngeal Cancer","A Prospective, Randomized, Three-Arm, Open-Label Clinical Trial Comparing Transoral CO₂ Laser Microsurgery, Volumetric Modulated Arc Therapy (VMAT), and MRI-Guided Stereotactic Ablative Radiotherapy (MRI-SABR) in the Treatment of Early-Stage Glottic Laryngeal Cancer","SMART - 1_1","Inclusion Criteria:\n\n* Age ≥18 years.\n* Histologically confirmed squamous cell carcinoma of the glottic larynx, including verrucous carcinoma.\n* Stage T1-T2N0 (8th TNM edition).\n* ECOG performance status 0-2.\n* Able to understand Lithuanian and complete questionnaires.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* AJCC stage III-IV laryngeal cancer.\n* Prior radiotherapy for head and neck cancer.\n* Pregnancy or breastfeeding.\n* Contraindications for radiotherapy or inability to follow-up.\n* Presence of another active malignancy.\n* Uncontrolled intercurrent illness (e.g., active infection, symptomatic CHF, unstable angina, clinically significant arrhythmia) or any condition that would preclude radiotherapy or adequate follow-up per investigator judgment.","ALL","18 Years",{"count":20,"type":21},105,"ESTIMATED","INTERVENTIONAL",[24],"NA","This randomized phase III trial will compare the outcomes of three treatment modalities for early-stage glottic laryngeal cancer (T1-T2N0): transoral CO₂ laser microsurgery (TLM), volumetric modulated arc therapy (VMAT), and MRI-guided stereotactic ablative radiotherapy (MRI-SABR). The primary endpoint is local control (LC). Secondary endpoints include laryngectomy-free survival (LFS), progression-free survival (PFS). overall survival (OS), functional voice, swallowing and breathing outcomes, treatment-related complications, and the evaluation of radiomic and dosiomic biomarkers. Patients will be randomized in a 1:1:1 ratio. Total planned enrollment is 105.",[27,28],"Laryngeal Neoplasm","Glottic Carcinoma",[30,31,32,33,34,35,36],"Early-stage glottic laryngeal cancer","transoral laser microsurgery","VMAT","MRI-SABR","stereotactic radiotherapy","radiomics","dosiomics","RECRUITING","2026-01-29",{"date":40,"type":41},"2026-02-05","ACTUAL",{"date":43,"type":41},"2024-09-01",{"date":45,"type":21},"2034-03",{"name":47,"class":48},"Viktoras Rudzianskas","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":68,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":49},"100432252","clinical-treatments-in-specialized-diseases-of-laryngeal-carcinoma-lc-and-hypopharyngeal-carcinoma-hpc-100432252","NCT04908696","Clinical Treatments in Specialized Diseases of Laryngeal Carcinoma (LC) and Hypopharyngeal Carcinoma (HPC)","Department of Otorhinolaryngology, Eye & ENT Hospital","Inclusion Criteria:\n\n* Laryngeal cancer: glottic type, supraglottic type, and subglottic type; hypopharyngeal cancer: pyriform sinus type, postcri-coid type, and posterior pharyngeal wall type.\n* T1, T2, T3, and T4 stage.\n* Age 18 - 90.\n* Male or female.\n* Good compliance.\n* No other severe related diseases that may impact the treatment (such as other tumors, severe heart, lung and central nervous system diseases, etc.).\n* Negative pregnancy test (for female patients with fertility).\n* Male patients with fertility and female patients with fertility and pregnancy risk must agree to use contraceptive methods throughout the study period, and continued until at least 6 months after the last dose of cisplatin. Female patients do not have fertility. Female patients with postmenopausal status.\n\nExclusion Criteria:\n\n* Patients who have previously been diagnosed with immunodeficiency or known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related diseases.\n* Patients with a known history of active tuberculosis (TB).\n* Pregnant women or lactating women.\n* The doctors believes that it is inappropriate for patients to participate in the trial: having, for example, severe acute or chronic medical conditions (including immune colitis, inflammatory bowel disease, non-infectious pneumonia, pulmonary fibrosis) or mental illness (including recent time \\[within the past year\\] or active suicidal ideation or behavior).","90 Years",{"count":59,"type":21},1000,"OBSERVATIONAL","For early stage laryngeal carcinoma and hypohparyngeal carcinoma (T1 and T2), transoral laser microsurgery, open partial laryngectomy, radiotherapy, and transoral robotic surgery were performed according to NCCN guidelines (2020).\n\nFor advanced stage laryngeal carcinoma and hypohparyngeal carcinoma (T3 and T4), surgical treatment ± postoperative adjuvant therapy, chemoradiotherapy, neoadjuvant therapy + radiotherapy\u002Fchemoradiotherapy, or neoadjuvant therapy + surgery + radiotherapy or chemoradiotherapy performed according to NCCN guidelines (2020).\n\nThis study plan to analyze the clinical ouctomes of different treatment for the same T stage disease. The overall survival rate, disease specific survival, disease free survival, local control, regional control, and laryngeal function preservation rate were analyzed in this study.",[28,63,64,65,66,67],"Supraglottic Carcinoma","Subglottic Carcinoma","Pyriform Sinus Carcinoma","Postcricoid Carcinoma","Posterior Pharyngeal Wall Carcinoma",[69,70,71,72],"Laryngeal carcinoma","Hypopharyngeal carcinoma","Surgery","Laryngeal function preservation treatment","2025-11-26",{"date":75,"type":41},"2025-12-04",{"date":77,"type":21},"2025-12-01",{"date":79,"type":21},"2027-12-01",{"name":81,"class":48},"Eye & ENT Hospital of Fudan University",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":94,"conditions":95,"keywords":101,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":107,"leadSponsor":109,"locationsCount":49},"100492157","phase-1-clinical-study-of-curcumin-in-preventing-postoperative-adhesion-of-bilateral-vocal-cords-100492157","NCT05688488","Clinical Study of Curcumin in Preventing Postoperative Adhesion of Bilateral Vocal Cords","Inclusion Criteria:\n\n1. Patients with bilateral vocal cord diseases who are going to undergo resection of bilateral vocal cord lesions endoscopically.\n2. Patients with bilateral vocal cord adhesion who are going to undergo incision of bilateral vocal cord adhesion endoscopically.\n\nExclusion Criteria:\n\n1. Patients with other laryngeal diseases.\n2. Patients with cardiac and pulmonary insufficiency.\n3. Patients unable to cooperate with the follow-up on time after surgery.\n4. Patients who refuse to sign the informed consent after notification.\n5. Patients who have a severe allergic disease or allergic history to a variety of drugs.\n6. Other circumstances that are not appropriate to be included in the clinical trial.","75 Years",{"count":90,"type":21},100,[92,93],"PHASE1","PHASE2","To provide a novel therapy idea and method to solve the clinical problem of postoperative adhesion of bilateral vocal cords, patients enrolled in this study will be applied with curcumin on both wound sites of bilateral vocal cords after the surgery on the bilateral vocal cord endoscopically.",[96,97,28,98,99,100],"Glottic Web of Larynx","Laryngeal Stenosis","Laryngeal Leucoplakia","Laryngeal Polyp","Laryngeal Papilloma",[102],"Curcumin","2023-05-05",{"date":105,"type":41},"2023-05-06",{"date":103,"type":21},{"date":108,"type":21},"2026-12-31",{"name":81,"class":48}]